Announcements Trials
Browse Landscape

Phase

Phase 2 8Phase 1 5Phase 3 2Phase 1/2 2Phase 4 1Phase 2/3 1

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Myeloid 2Lymphoid 2

Conditions

Carcinoma, Non-Small-Cell Lung 438Neoplasms 363Breast Neoplasms 261Colorectal Neoplasms 244Neoplasm Metastasis 216Melanoma 210Leukemia, Myeloid, Acute 188Multiple Myeloma 187Pancreatic Neoplasms 182Ovarian Neoplasms 181Recurrence 175Prostatic Neoplasms 161Lymphoma, Non-Hodgkin 142Stomach Neoplasms 133Squamous Cell Carcinoma of Head and Neck 128Lung Neoplasms 125Lymphoma 121Carcinoma, Hepatocellular 117Carcinoma, Renal Cell 102Triple Negative Breast Neoplasms 100Leukemia, Lymphocytic, Chronic, B-Cell 99Glioblastoma 97Advanced Solid Tumor 94Leukemia 93Small Cell Lung Carcinoma 91Lymphoma, Large B-Cell, Diffuse 90Head and Neck Neoplasms 87Advanced Solid Tumors 85Endometrial Neoplasms 81Myelodysplastic Syndromes 78

Interventions

nilotinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × INDUSTRY × Mastocytosis, Systemic × Clear all
NCT03214666 2022-11-10

GTB-3550 Tri-Specific Killer Engager (TriKE®) for High Risk Hematological Malignancies

GT Biopharma, Inc.

Phase 1/2 Terminated
12 enrolled 20 charts
LymphoidMyeloidOther hematologic neoplasm

Leukemia, Mast-Cell, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Mastocytosis, Systemic

NCT00109707 2021-06-29

A Study of Oral AMN107 in Adults With Chronic Myelogenous Leukemia (CML) or Other Hematologic Malignancies

Novartis

Phase 1/2 Completed
507 enrolled 16 charts
LymphoidMyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Hypereosinophilic Syndrome, Mastocytosis, Systemic, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡